Transporter Pharmacogenetics and Statin Toxicity

No significant effect ofABCB1haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin

(2009) Jenni E. Keskitalo et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

ABCG2 Polymorphism Markedly Affects the Pharmacokinetics of Atorvastatin and Rosuvastatin

(2009) J E Keskitalo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Different effects of theABCG2c.421C>A SNP on the pharmacokinetics of fluvastatin, pravastatin and simvastatin

(2009) Jenni E Keskitalo et al.   PHARMACOGENOMICS

ABCG2: A perspective

(2008) Robert W. Robey et al.   ADVANCED DRUG DELIVERY REVIEWS

ABCB1 Haplotypes Differentially Affect the Pharmacokinetics of the Acid and Lactone Forms of Simvastatin and Atorvastatin

(2008) JE Keskitalo et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Involvement of Multiple Transporters in the Hepatobiliary Transport of Rosuvastatin

(2008) S. Kitamura et al.   DRUG METABOLISM AND DISPOSITION

SLCO1B1Variants and Statin-Induced Myopathy — A Genomewide Study

(2008)   NEW ENGLAND JOURNAL OF MEDICINE

The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15

(2008) Jian Wei Deng et al.   Pharmacogenetics and Genomics

Global analysis of genetic variation in SLCO1B1

(2007) Marja K Pasanen et al.   PHARMACOGENOMICS